Silence Therapeutics Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Der Gewinn von Silence Therapeutics wird voraussichtlich um 19.7% pro Jahr zurückgehen, während der Jahresumsatz um 66.7% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 15.1% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -31.2% betragen.
Wichtige Informationen
-19.7%
Wachstumsrate der Gewinne
15.11%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 27.2% |
| Wachstumsrate der Einnahmen | 66.7% |
| Zukünftige Eigenkapitalrendite | -31.16% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 14 Aug 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Analyseartikel • Aug 12
Silence Therapeutics plc (NASDAQ:SLN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...Analyseartikel • May 11
Silence Therapeutics plc (NASDAQ:SLN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The analysts might have been a bit too bullish on Silence Therapeutics plc ( NASDAQ:SLN ), given that the company fell...Analyseartikel • Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
As you might know, Silence Therapeutics plc ( NASDAQ:SLN ) last week released its latest second-quarter, and things did...Recent updates
Seeking Alpha • Aug 19
Silence Therapeutics: Making Some Recent Noise
Summary Silence Therapeutics have moved higher on recent trial results, and the company also addressed its funding needs. SLN's lead asset, divesiran for polycythemia vera, faces significant competition from Takeda's rusfertide, which is likely to launch in Q4 2026. Analyst firms are currently constructive on the company's prospects. An analysis around Silence Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Narrative-Update • Aug 12
SLN: Phase 2 Success And Equity Programs Will Drive Upside Potential
Analysts have raised their fair value estimate for Silence Therapeutics from $31.20 to $35.60, citing updated assumptions related to the discount rate, revenue growth, profit margin, and future P/E levels. What’s in the News for Silence Therapeutics Silence Therapeutics reported positive topline results from the Phase 2 SANRECO trial of divesiran in 48 phlebotomy dependent polycythemia vera patients.Narrative-Update • Jun 15
SLN: Upcoming Phase 2 Data And ATM Program Will Shape Upside Potential
Analysts have kept their $31.20 price target for Silence Therapeutics unchanged, with only minor tweaks to inputs such as discount rate, profit margin and forward P/E assumptions informing the latest update. What's in the News Silence Therapeutics presented follow-up and quality-of-life data from the Phase 1 SANRECO study of divesiran in 21 phlebotomy-dependent polycythemia vera patients at the European Hematology Association 2026 Annual Congress, showing fewer required phlebotomies during and after treatment and reported improvements in PV-related symptoms and overall quality of life.Narrative-Update • Jun 01
SLN: Future Offering Program Will Shape Upside Risk Reward Profile
Analysts have adjusted their price target on Silence Therapeutics to $31.20. This reflects updated assumptions around growth, profitability and a higher future P/E multiple that together indicate a different risk and reward profile than before.Analyseartikel • Feb 05
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive
To the annoyance of some shareholders, Silence Therapeutics plc ( NASDAQ:SLN ) shares are down a considerable 27% in...Analyseartikel • Jan 31
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analyseartikel • Oct 19
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analyseartikel • Sep 28
Pinning Down Silence Therapeutics plc's (NASDAQ:SLN) P/S Is Difficult Right Now
With a median price-to-sales (or "P/S") ratio of close to 9.9x in the Biotechs industry in the United States, you could...Analyseartikel • Aug 13
Newsflash: Silence Therapeutics plc (NASDAQ:SLN) Analysts Have Been Trimming Their Revenue Forecasts
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...Analyseartikel • Aug 12
Silence Therapeutics plc (NASDAQ:SLN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...Narrative-Update • Aug 08
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The upward revision in Silence Therapeutics’ price target reflects significantly improved consensus revenue growth forecasts and a lower future P/E multiple, resulting in an increased fair value estimate from $32.37 to $37.26. What's in the News Silence Therapeutics approved the application of Article 159 of its articles of association, effective from the recent AGM to the next annual general meeting.Analyseartikel • May 11
Silence Therapeutics plc (NASDAQ:SLN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The analysts might have been a bit too bullish on Silence Therapeutics plc ( NASDAQ:SLN ), given that the company fell...Analyseartikel • May 06
Silence Therapeutics plc's (NASDAQ:SLN) Price Is Right But Growth Is Lacking After Shares Rocket 50%
Those holding Silence Therapeutics plc ( NASDAQ:SLN ) shares would be relieved that the share price has rebounded 50...
Neues Narrative • Apr 01
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The company's strategic partnerships and collaborations could reduce financial risk and enhance revenue growth through shared commercialization and milestone payments.Analyseartikel • Mar 22
Silence Therapeutics plc (NASDAQ:SLN) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Silence Therapeutics plc ( NASDAQ:SLN ) share price has dived 29% in the last...Analyseartikel • Mar 06
These Analysts Think Silence Therapeutics plc's (NASDAQ:SLN) Sales Are Under Threat
Market forces rained on the parade of Silence Therapeutics plc ( NASDAQ:SLN ) shareholders today, when the analysts...Analyseartikel • Mar 04
We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyseartikel • Jan 28
Risks Still Elevated At These Prices As Silence Therapeutics plc (NASDAQ:SLN) Shares Dive 26%
Unfortunately for some shareholders, the Silence Therapeutics plc ( NASDAQ:SLN ) share price has dived 26% in the last...Analyseartikel • Dec 10
Silence Therapeutics plc (NASDAQ:SLN) May Have Run Too Fast Too Soon With Recent 54% Price Plummet
Silence Therapeutics plc ( NASDAQ:SLN ) shareholders that were waiting for something to happen have been dealt a blow...Analyseartikel • Oct 04
Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio
You may think that with a price-to-sales (or "P/S") ratio of 38.4x Silence Therapeutics plc ( NASDAQ:SLN ) is a stock...Analyseartikel • Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
As you might know, Silence Therapeutics plc ( NASDAQ:SLN ) last week released its latest second-quarter, and things did...Analyseartikel • Jun 17
Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit
You may think that with a price-to-sales (or "P/S") ratio of 26.8x Silence Therapeutics plc ( NASDAQ:SLN ) is a stock...Analyseartikel • May 21
Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. By way of example, Silence...Analyseartikel • Feb 07
Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Silence Therapeutics plc ( NASDAQ:SLN ) shareholders will have a reason to smile today, with the analysts making...Analyseartikel • Nov 27
Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Silence Therapeutics plc ( NASDAQ:SLN ) shares have had a really impressive month, gaining 65% after a shaky period...Seeking Alpha • Sep 08
Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
U.K.-based clinical-stage biotech Silence Therapeutics plc (NASDAQ:SLN) announced Thursday that the FDA granted Fast Track Designation to SLN124 as a treatment for polycythemia vera (PV), a type of blood cancer. SLN124, belonging to a drug class called short interfering ribonucleic acid (siRNA) therapeutics, is set to undergo a Phase 1/2 study in PV this year. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling them to reach patients sooner. In a clinical trial last year, SLN124 indicated proof of mechanism and was well tolerated among healthy volunteers.Seeking Alpha • Aug 12
Silence Therapeutics prices 5.95M ADSs at $9.50/share
Silence Therapeutics (NASDAQ:SLN) has priced an underwritten offering of 5.95M American Depositary Shares, each representing three ordinary shares, at a price of $9.50/ADS, for aggregate gross proceeds of ~$56.5M. All of the ADSs are being offered by Silence. Offering is expected to close on or about August 16, 2022. Silence intends to use the net proceeds of the offering, together with its existing cash and cash equivalents to fund the advancement of its clinical trials, including its Phase 2 trial of SLN360 in ASCVD and its Phase 1/2 trial of SLN124 in polycythemia vera, as well as expansion of pipeline programs, working capital and general corporate purposes.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 0 | -105 | -118 | -117 | 5 |
| 12/31/2027 | 1 | -90 | -93 | -91 | 7 |
| 12/31/2026 | 0 | -56 | -45 | -40 | 7 |
| 6/30/2026 | 1 | -60 | -42 | -42 | N/A |
| 3/31/2026 | 1 | -75 | -66 | -66 | N/A |
| 12/31/2025 | 1 | -89 | -62 | -62 | N/A |
| 9/30/2025 | 26 | -65 | -73 | -72 | N/A |
| 6/30/2025 | 27 | -79 | -87 | -87 | N/A |
| 3/31/2025 | 28 | -72 | -71 | -71 | N/A |
| 12/31/2024 | 43 | -45 | -68 | -68 | N/A |
| 9/30/2024 | 18 | -73 | -53 | -53 | N/A |
| 6/30/2024 | 22 | -50 | -36 | -35 | N/A |
| 3/31/2024 | 33 | -44 | -49 | -49 | N/A |
| 12/31/2023 | 32 | -54 | -50 | -49 | N/A |
| 9/30/2023 | 34 | -52 | -50 | -50 | N/A |
| 6/30/2023 | 36 | -53 | -58 | -58 | N/A |
| 3/31/2023 | 29 | -53 | -48 | -48 | N/A |
| 12/31/2022 | 22 | -50 | -58 | -57 | N/A |
| 9/30/2022 | 18 | -40 | -39 | -38 | N/A |
| 6/30/2022 | 19 | -47 | -37 | -36 | N/A |
| 3/31/2022 | 20 | -51 | 4 | 6 | N/A |
| 12/31/2021 | 17 | -53 | 7 | 9 | N/A |
| 9/30/2021 | 15 | -57 | 4 | 5 | N/A |
| 6/30/2021 | 14 | -57 | 2 | 3 | N/A |
| 3/31/2021 | 11 | -49 | -33 | -32 | N/A |
| 12/31/2020 | 7 | -45 | -15 | -15 | N/A |
| 9/30/2020 | 4 | -33 | 0 | 1 | N/A |
| 6/30/2020 | 2 | -28 | 15 | 16 | N/A |
| 3/31/2020 | 1 | -26 | N/A | 9 | N/A |
| 12/31/2019 | 0 | -26 | N/A | 2 | N/A |
| 9/30/2019 | 0 | -23 | N/A | -10 | N/A |
| 6/30/2019 | N/A | -23 | N/A | -23 | N/A |
| 3/31/2019 | N/A | -24 | N/A | -23 | N/A |
| 12/31/2018 | N/A | -23 | N/A | -21 | N/A |
| 9/30/2018 | N/A | -15 | N/A | -20 | N/A |
| 6/30/2018 | N/A | -6 | N/A | -18 | N/A |
| 3/31/2018 | 0 | -4 | N/A | -17 | N/A |
| 12/31/2017 | 0 | -2 | N/A | -13 | N/A |
| 9/30/2017 | 1 | -7 | N/A | -12 | N/A |
| 6/30/2017 | 1 | -12 | N/A | -11 | N/A |
| 3/31/2017 | 1 | -11 | N/A | -12 | N/A |
| 12/31/2016 | 1 | -10 | N/A | -12 | N/A |
| 9/30/2016 | 0 | -10 | N/A | -13 | N/A |
| 6/30/2016 | N/A | -10 | N/A | -12 | N/A |
| 3/31/2016 | N/A | -10 | N/A | -13 | N/A |
| 12/31/2015 | N/A | -10 | N/A | -12 | N/A |
| 9/30/2015 | 0 | -12 | N/A | -13 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: SLN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: SLN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: SLN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: SLNDie Einnahmen des Unternehmens (66.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (12.9% pro Jahr).
Hohe Wachstumseinnahmen: SLNDie Einnahmen des Unternehmens (66.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: SLN wird voraussichtlich in 3 Jahren unrentabel sein.
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/20 02:25 |
| Aktienkurs zum Tagesende | 2026/08/20 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Silence Therapeutics plc wird von 14 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Howard Miller | Canaccord Genuity |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Keay Nakae | Chardan Capital Markets, LLC |